Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Elucidation of N 1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters.

Miyake T, Mizuno T, Takehara I, Mochizuki T, Kimura M, Matsuki S, Irie S, Watanabe N, Kato Y, Ieiri I, Maeda K, Ando O, Kusuhara H.

Drug Metab Dispos. 2019 Nov;47(11):1270-1280. doi: 10.1124/dmd.119.087262. Epub 2019 Sep 11.

PMID:
31511257
2.

Effect of Rifampicin on the Plasma Concentrations of Bile Acid-O-Sulfates in Monkeys and Human Liver-Transplanted Chimeric Mice With or Without Bile Flow Diversion.

Takehara I, Watanabe N, Mori D, Ando O, Kusuhara H.

J Pharm Sci. 2019 Aug;108(8):2756-2764. doi: 10.1016/j.xphs.2019.03.021. Epub 2019 Mar 21.

PMID:
30905707
3.

Correction to: Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers.

Takehara I, Yoshikado T, Ishigame K, Mori D, Furihata KI, Watanabe N, Ando O, Maeda K, Kusuhara H, Sugiyama Y.

Pharm Res. 2019 Feb 21;36(4):55. doi: 10.1007/s11095-019-2585-8.

PMID:
30790061
4.

Pharmacokinetics, Metabolism, and Excretion of [14C]Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans.

Yamada M, Mendell J, Takakusa H, Shimizu T, Ando O.

Drug Metab Dispos. 2019 Mar;47(3):340-349. doi: 10.1124/dmd.118.084897. Epub 2018 Dec 12.

PMID:
30541878
5.

Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys.

Nagai Y, Oitate M, Shiozawa H, Ando O.

Xenobiotica. 2019 Sep;49(9):1086-1096. doi: 10.1080/00498254.2018.1531158. Epub 2019 Jan 4.

PMID:
30351177
6.

In vivo multiple metabolic pathways for a novel G protein-coupled receptor 119 agonist DS-8500a in rats: involvement of the 1,2,4-oxadiazole ring-opening reductive reaction in livers under anaerobic conditions.

Makino C, Watanabe A, Deguchi T, Shiozawa H, Schreck I, Rozehnal V, Ishizuka T, Watanabe N, Ando O, Murayama N, Yamazaki H.

Xenobiotica. 2019 Aug;49(8):961-969. doi: 10.1080/00498254.2018.1514545. Epub 2018 Sep 28.

PMID:
30124356
7.

Interaction of Nevirapine with the Peptide Binding Groove of HLA-DRB1*01:01 and Its Effect on the Conformation of HLA-Peptide Complex.

Hirasawa M, Hagihara K, Abe K, Ando O, Hirayama N.

Int J Mol Sci. 2018 Jun 4;19(6). pii: E1660. doi: 10.3390/ijms19061660.

8.

Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers.

Takehara I, Yoshikado T, Ishigame K, Mori D, Furihata KI, Watanabe N, Ando O, Maeda K, Sugiyama Y, Kusuhara H.

Pharm Res. 2018 May 10;35(7):138. doi: 10.1007/s11095-018-2416-3. Erratum in: Pharm Res. 2019 Feb 21;36(4):55.

PMID:
29748935
9.

Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys.

Karibe T, Imaoka T, Abe K, Ando O.

Drug Metab Dispos. 2018 May;46(5):667-679. doi: 10.1124/dmd.117.078931. Epub 2018 Jan 22.

PMID:
29358184
10.

Investigation of Glycochenodeoxycholate Sulfate and Chenodeoxycholate Glucuronide as Surrogate Endogenous Probes for Drug Interaction Studies of OATP1B1 and OATP1B3 in Healthy Japanese Volunteers.

Takehara I, Terashima H, Nakayama T, Yoshikado T, Yoshida M, Furihata K, Watanabe N, Maeda K, Ando O, Sugiyama Y, Kusuhara H.

Pharm Res. 2017 Aug;34(8):1601-1614. doi: 10.1007/s11095-017-2184-5. Epub 2017 May 26.

PMID:
28550384
11.

In Silico and In Vitro Analysis of Interaction between Ximelagatran and Human Leukocyte Antigen (HLA)-DRB1*07:01.

Hirasawa M, Hagihara K, Abe K, Ando O, Hirayama N.

Int J Mol Sci. 2017 Mar 24;18(4). pii: E694. doi: 10.3390/ijms18040694.

12.

Difference in Mechanism-Based Inhibition of Cytochrome P450 3A4 and 3A5 by a Series of Fluoroquinolone Antibacterial Agents.

Watanabe A, Takakusa H, Kimura T, Inoue SI, Kusuhara H, Ando O.

Drug Metab Dispos. 2017 Mar;45(3):336-341. doi: 10.1124/dmd.116.073783. Epub 2016 Dec 14.

PMID:
27974381
13.

Studies on novel HIF activators, A-503451sII: biological activities of A-503451A.

Kobayashi H, Ohyama T, Kitamura-Miyazaki M, Hirota-Takahata Y, Ando O.

J Antibiot (Tokyo). 2016 Oct;69(10):754-758. doi: 10.1038/ja.2016.20. Epub 2016 Mar 9.

PMID:
26956797
14.

Studies on novel HIF activators, A-503451s.I. Producing organism, fermentation, isolation and structural elucidation.

Hirota-Takahata Y, Kobayashi H, Kizuka M, Ohyama T, Kitamura-Miyazaki M, Suzuki Y, Fujiwara M, Nakajima M, Ando O.

J Antibiot (Tokyo). 2016 Oct;69(10):747-753. doi: 10.1038/ja.2016.17. Epub 2016 Mar 9.

PMID:
26956789
15.

Analysis of Mechanism-Based Inhibition of CYP 3A4 by a Series of Fluoroquinolone Antibacterial Agents.

Watanabe A, Takakusa H, Kimura T, Inoue S, Kusuhara H, Ando O.

Drug Metab Dispos. 2016 Oct;44(10):1608-16. doi: 10.1124/dmd.116.071654. Epub 2016 Jul 28.

PMID:
27469000
16.

Identification and biological activity of ogipeptins, novel LPS inhibitors produced by marine bacterium.

Kozuma S, Hirota-Takahata Y, Fukuda D, Kuraya N, Nakajima M, Ando O.

J Antibiot (Tokyo). 2017 Jan;70(1):79-83. doi: 10.1038/ja.2016.81. Epub 2016 Jul 6.

PMID:
27381520
17.

Ogipeptins, novel inhibitors of LPS: physicochemical properties and structural elucidation.

Hirota-Takahata Y, Kozuma S, Kuraya N, Fukuda D, Nakajima M, Takatsu T, Ando O.

J Antibiot (Tokyo). 2017 Jan;70(1):84-89. doi: 10.1038/ja.2016.61. Epub 2016 Jun 22.

PMID:
27328866
18.

IQGAP1 selectively interacts with K-Ras but not with H-Ras and modulates K-Ras function.

Matsunaga H, Kubota K, Inoue T, Isono F, Ando O.

Biochem Biophys Res Commun. 2014 Feb 14;444(3):360-4. doi: 10.1016/j.bbrc.2014.01.041. Epub 2014 Jan 22.

PMID:
24462863
19.

Pedopeptins, novel inhibitors of LPS: taxonomy of producing organism, fermentation, isolation, physicochemical properties and structural elucidation.

Hirota-Takahata Y, Kozuma S, Kuraya N, Fukuda D, Nakajima M, Ando O.

J Antibiot (Tokyo). 2014 Mar;67(3):243-51. doi: 10.1038/ja.2013.122. Epub 2013 Dec 4.

PMID:
24301185
20.

Screening and biological activities of pedopeptins, novel inhibitors of LPS produced by soil bacteria.

Kozuma S, Hirota-Takahata Y, Fukuda D, Kuraya N, Nakajima M, Ando O.

J Antibiot (Tokyo). 2014 Mar;67(3):237-42. doi: 10.1038/ja.2013.121. Epub 2013 Nov 27.

PMID:
24281661
21.

A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.

Oike T, Ogiwara H, Tominaga Y, Ito K, Ando O, Tsuta K, Mizukami T, Shimada Y, Isomura H, Komachi M, Furuta K, Watanabe S, Nakano T, Yokota J, Kohno T.

Cancer Res. 2013 Sep 1;73(17):5508-18. doi: 10.1158/0008-5472.CAN-12-4593. Epub 2013 Jul 19.

22.

IDH1 and IDH2 have critical roles in 2-hydroxyglutarate production in D-2-hydroxyglutarate dehydrogenase depleted cells.

Matsunaga H, Futakuchi-Tsuchida A, Takahashi M, Ishikawa T, Tsuji M, Ando O.

Biochem Biophys Res Commun. 2012 Jul 6;423(3):553-6. doi: 10.1016/j.bbrc.2012.06.002. Epub 2012 Jun 7.

PMID:
22683334
23.

Structural basis of digoxin that antagonizes RORgamma t receptor activity and suppresses Th17 cell differentiation and interleukin (IL)-17 production.

Fujita-Sato S, Ito S, Isobe T, Ohyama T, Wakabayashi K, Morishita K, Ando O, Isono F.

J Biol Chem. 2011 Sep 9;286(36):31409-17. doi: 10.1074/jbc.M111.254003. Epub 2011 Jul 6.

24.

Long-term effects of the trehalase inhibitor trehazolin on trehalase activity in locust flight muscle.

Wegener G, Macho C, Schlöder P, Kamp G, Ando O.

J Exp Biol. 2010 Nov 15;213(Pt 22):3852-7. doi: 10.1242/jeb.042028.

25.

Fate and effects of the trehalase inhibitor trehazolin in the migratory locust (Locusta migratoria).

Liebl M, Nelius V, Kamp G, Ando O, Wegener G.

J Insect Physiol. 2010 Jun;56(6):567-74. doi: 10.1016/j.jinsphys.2009.11.021. Epub 2009 Dec 10.

PMID:
19958774
26.

Synthesis and properties of ENA oligonucleotides targeted to human telomerase RNA subunit.

Horie M, Morita K, Kawakami J, Tsutsumi S, Ando O, Koizumi M.

Nucleic Acids Symp Ser (Oxf). 2005;(49):171-2.

PMID:
17150688
27.

Differential activation of IFN regulatory factor (IRF)-3 and IRF-5 transcription factors during viral infection.

Cheng TF, Brzostek S, Ando O, Van Scoy S, Kumar KP, Reich NC.

J Immunol. 2006 Jun 15;176(12):7462-70.

28.

Comparison between properties of 2'-O,4'-C-ethylene-bridged nucleic acid (ENA) phosphorothioate oligonucleotides and N3'-P5' thiophosphoramidate oligonucleotides.

Horie M, Morita K, Kawakami J, Ando O, Koizumi M, Tsutsumi S.

Nucleosides Nucleotides Nucleic Acids. 2006 Mar;25(3):231-42.

PMID:
16629117
29.

Cotreatment with interferon-alpha and -gamma reduces liver fibrosis in a rat model.

Takahara T, Sugiyama K, Zhang LP, Ando O, Fujii M, Yata Y, Bo J, Xue F, Minemura M, Watanabe A.

Hepatol Res. 2004 Mar;28(3):146-154.

PMID:
15036071
30.
31.

The toxic and lethal effects of the trehalase inhibitor trehazolin in locusts are caused by hypoglycaemia.

Wegener G, Tschiedel V, Schlöder P, Ando O.

J Exp Biol. 2003 Apr;206(Pt 7):1233-40.

32.

Ley glycolipid-recognizing monoclonal antibody inhibits procoagulant activity and metastasis of human adenocarcinoma.

Inufusa H, Adachi T, Kiyokawa T, Nakatani Y, Wakano T, Nakamura M, Okuno K, Shiozaki H, Yamamoto S, Suzuki M, Ando O, Kurimoto M, Miyake M, Yasutomi M.

Int J Oncol. 2001 Nov;19(5):941-6.

PMID:
11604991
33.
34.
35.

Processing glucosidase inhibition by 1-azafagomine.

Muroi M, Ando O, Bols M, Takatsuki A.

Biosci Biotechnol Biochem. 2000 May;64(5):1103-5.

36.

High expression of glycosphingolipids involved in procoagulant activity of cancer cells.

Suzuki M, Ando O, Ohta T, Inufusa H, Adachi T, Yasutomi M, Kurimoto M.

Oncol Rep. 1999 Jan-Feb;6(1):113-5.

PMID:
9864412
37.

IL-12 promotes the accessory cell function of epidermal Langerhans cells.

Suemoto Y, Ando O, Kurimoto M, Horikawa T, Ichihashi M.

J Dermatol Sci. 1998 Nov;18(2):98-108.

PMID:
9833976
38.

Correlation of prognosis of breast cancer patients and expression of Ley which acts as a cofactor of tumor procoagulant.

Inufusa H, Nakatani Y, Adachi T, Wakano T, Nakajima A, Nakamura M, Suzuki M, Ando O, Kurimoto M, Miyake M, Shindo K, Yasutomi M.

Int J Oncol. 1998 Sep;13(3):481-7.

PMID:
9683782
39.

Generation of a monoclonal antibody that inhibits the procoagulant activity of various cancer cell lines.

Inufusa H, Adachi T, Suzuki M, Ando O, Ohta T, Kurimoto M, Nakatani Y, Nakamura M, Yasutomi M.

Cancer. 1998 Apr 15;82(8):1563-9.

PMID:
9554535
40.

Le(y) glycolipid acts as a co-factor for tumor procoagulant activity.

Suzuki M, Inufusa H, Yamamoto S, Hamada T, Aga M, Ando O, Ohta T, Yasutomi M, Kurimoto M.

Int J Cancer. 1997 Dec 10;73(6):903-9.

41.

Trehazolin, a slow, tight-binding inhibitor of silkworm trehalase.

Ando O, Nakajima M, Kifune M, Fang H, Tanzawa K.

Biochim Biophys Acta. 1995 Jun 9;1244(2-3):295-302.

PMID:
7599147
42.

Establishment of new interferon-gamma-resistant mutant cells with dominant phenotypes.

Ohta T, Ando O, Kurimoto M.

J Interferon Cytokine Res. 1995 Feb;15(2):153-60.

PMID:
8590319
43.

Analyses of mixed melanogenesis in tyrosinase cDNA-transfected human amelanotic melanoma cells.

Ando O, Mishima Y, Hanada S, Suemoto Y, Atobe J, Kurimoto M.

J Invest Dermatol. 1993 Dec;101(6):864-70.

44.

Isolation of trehalamine, the aglycon of trehazolin, from microbial broths and characterization of trehazolin related compounds.

Ando O, Nakajima M, Hamano K, Itoi K, Takahashi S, Takamatsu Y, Sato A, Enokita R, Okazaki T, Haruyama H, et al.

J Antibiot (Tokyo). 1993 Jul;46(7):1116-25.

45.

Tyrosinase gene transcription and its control by melanogenic inhibitors.

Ando S, Ando O, Suemoto Y, Mishima Y.

J Invest Dermatol. 1993 Feb;100(2 Suppl):150S-155S.

46.

Trehazolin, a new trehalase inhibitor.

Ando O, Satake H, Itoi K, Sato A, Nakajima M, Takahashi S, Haruyama H, Ohkuma Y, Kinoshita T, Enokita R.

J Antibiot (Tokyo). 1991 Oct;44(10):1165-8. No abstract available.

47.

Synerazol, a new antifungal antibiotic.

Ando O, Satake H, Nakajima M, Sato A, Nakamura T, Kinoshita T, Furuya K, Haneishi T.

J Antibiot (Tokyo). 1991 Apr;44(4):382-9.

48.

[Remodeling of the gingivae after the forced eruption].

Ando O.

Nihon Rinsho Shishubyo Danwakai Kaishi. 1990 Dec 1;8:20-7. Japanese. No abstract available.

PMID:
2131103
49.

Cloning and nucleotide sequence of the gene encoding arginine deiminase of Mycoplasma arginini.

Ohno T, Ando O, Sugimura K, Taniai M, Suzuki M, Fukuda S, Nagase Y, Yamamoto K, Azuma I.

Infect Immun. 1990 Nov;58(11):3788-95.

50.

Monoclonal antibodies as probes for monitoring the denaturation process of bovine beta-lactoglobulin.

Kaminogawa S, Shimizu M, Ametani A, Hattori M, Ando O, Hachimura S, Nakamura Y, Totsuka M, Yamauchi K.

Biochim Biophys Acta. 1989 Sep 14;998(1):50-6.

PMID:
2477067

Supplemental Content

Support Center